Lucinda Crabtree Takes Helm as CFO of Oxford Biomedica
![Lucinda Crabtree Takes Helm as CFO of Oxford Biomedica](https://investorshangout.com/images/blog/ihnews-Lucinda%20Crabtree%20Takes%20Helm%20as%20CFO%20of%20Oxford%20Biomedica.jpg)
Lucinda Crabtree Joins Oxford Biomedica as CFO
Oxford Biomedica plc (LSE: OXB), a leading organization in cell and gene therapy manufacturing, has welcomed Lucinda Crabtree, Ph.D., as its new Chief Financial Officer (CFO) and board member. Her extensive background in finance and investment, particularly in the pharmaceutical sector, positions her to be a key player in the company's future growth.
Experience and Background of Lucinda Crabtree
Before joining Oxford Biomedica, Lucinda Crabtree served as the CFO at MorphoSys AG, where she adeptly managed a financial team across different regions, including the US and Germany. Her journey in finance includes pivotal leadership roles at Autolus Therapeutics, which operates on the Nasdaq. This experience clearly demonstrates her capability to navigate the complexities of the finance sector, especially in biopharmaceuticals.
Strong Foundation in Financial Leadership
Crabtree’s background is further enriched by her experience in investment and banking. She has held influential positions at prestigious institutions such as Woodford Investment Management, Goldman Sachs, and Jefferies. This combination of roles has equipped her with a unique perspective on both financial management and market trends.
Dr. Frank Mathias on Crabtree's Appointment
Dr. Frank Mathias, the Chief Executive Officer of Oxford Biomedica, expressed enthusiasm regarding Crabtree's appointment. He stated, "We are thrilled that Lucy has joined Oxford Biomedica as our new CFO and Board member. Lucy brings a wealth of experience from her roles as a CFO and time as a healthcare investor and equity research analyst. Her experience will be invaluable as we grow our international position as a leading cell and gene therapy CDMO.”
Lucinda's Vision for Oxford Biomedica
Lucinda Crabtree has voiced her excitement about this new challenge, saying, “I am excited to be joining Oxford Biomedica as CFO. I firmly believe in the Company’s growth strategy and am looking forward to working with the Board and the rest of the leadership team. Together, I am confident we will fulfill our mission of enabling our growing client base to deliver life-changing therapies to patients.”
The Mission of Oxford Biomedica
Oxford Biomedica is committed to delivering innovative therapies that create substantial benefits for patients. The company, recognized for its pioneering work in cell and gene therapy, has built a reputation as a contract development and manufacturing organization (CDMO) focused on quality and innovation.
About Oxford Biomedica
With over 25 years of expertise in viral vectors, Oxford Biomedica collaborates with some of the leading pharmaceutical and biotechnology firms worldwide. They specialize in vital areas like viral vector development and manufacturing, focusing on technologies such as lentivirus and adeno-associated virus (AAV).
Innovative Technologies and Capabilities
Oxford Biomedica's capabilities extend from initial development stages to full commercialization, supported by comprehensive quality-assurance systems and deep regulatory knowledge. The team offers a variety of unique technologies ideal for viral vector manufacturing, including advanced production systems and innovative cell lines.
Contact Information
For inquiries, reach out to:
Oxford Biomedica plc:
Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR Consilium:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
Frequently Asked Questions
Who is Lucinda Crabtree?
Lucinda Crabtree is the newly appointed Chief Financial Officer of Oxford Biomedica, bringing extensive experience from her previous roles in the pharmaceutical sector.
What is the role of the Chief Financial Officer?
The CFO oversees the financial operations of the company, strategizing and managing the financial risks while aligning with the company's growth objectives.
Why did Lucinda join Oxford Biomedica?
Lucinda joined to leverage her experience in finance within a company committed to developing life-changing therapeutic solutions for patients.
What is Oxford Biomedica's mission?
Oxford Biomedica aims to facilitate the delivery of innovative cell and gene therapies to patients globally.
What technologies does Oxford Biomedica use?
They utilize a range of technologies for viral vector manufacturing, emphasizing advanced systems for optimal production and quality assurance.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Biodegradable Medical Plastics Market to Reach $4.5 Billion
- Healthcare Waste Management Market Analysis and Future Growth
- Oil and Gas Security Market Set to Hit USD 43.74 Billion
- Software Defined Data Center Market Growth Insights
- Understanding Net Asset Value of Middlefield Canadian Income PCC
- Disclosure of Interests in Keywords Studios Plc Securities
- Growth of Bike Sharing Market Expected to Hit $18.64 Billion
- Plant-Based Fiber Market Forecast: Growth to USD 678.9 Million
- Novo Resources to Showcase at Gold Coast Investor Conference
- Market Values of Tech Companies Decline Amid Concerns
- Biopolymers Market Forecast to Double by 2031
- STMicroelectronics Updates on Share Repurchase Program
- Alliance Trust PLC Announces Latest Net Asset Value
- Bitcoin Experiences Decline Amid Seasonal Trends
- ForexPros.org Makes Waves with Nasdaq Debut
- The Future of DexCom: Growth and Opportunities Ahead
- Four Compelling Reasons to Invest in Walmart Right Now
- Growing Demand for 3D Surveillance Cameras by 2030
- The Impact of Dollar Weakness on Global Economies
- Industry 5.0 Market Growth Forecast: USD 663.68 Billion
- REA Group Explores Acquisition of Rightmove Plc
- Exploring the Future of Bitcoin: 3 Key Factors
- Investing in Brookfield Infrastructure: Strong Dividend Growth
- Two-Wheeler Accessory Market Forecast to Reach $66.83 Billion
- Impact of Real Estate Market Assessments on Risk Assets
Recent Articles
- Alliance Trust PLC Announces Latest Net Asset Value
- Global Fine Chemicals Market Growth and Trends Ahead
- Abeona Therapeutics Grants New Employee Equity Awards
- Admirals Group AS Announces Strong 2024 Financial Results
- Man Group PLC Disclosure of Interests in International Paper
- Swiss Franc's Rise and Its Impact on Trading Strategies
- Exor N.V. Report: Progress on Share Buyback Program
- Architectural Lighting Market Poised for Significant Growth
- Bedford Metals Expands Uranium Exploration Plans
- Voting Rights Overview for ICG Enterprise Trust
- VGP NV: Understanding Voting Rights and Share Capital
- Understanding Current Mortgage Rates and Refinancing Options
- Cytokinetics Showcases Aficamten Safety Insights at ESC 2024
- New World Development Faces Challenges Amid Property Decline
- Altria Group's Dividend Growth Amid Market Changes
- Public Acquires Carta's Brokerage Business for Growth
- Top REITs for Long-Term Investment Opportunities
- Understanding Palantir Technologies and S&P 500 Eligibility
- Spartan Capital Partners with Safe Pro Group in IPO Launch
- Shaquille O'Neal's Financial Lesson on Investing
- Proactis SA Financial Insights for the First Half of 2024
- Middlefield Canadian Income PCC Updates Net Asset Value
- Public Disclosure of Interests in Balanced Commercial Property Trust
- Electric Toothbrush Market Growth Forecast to 2032
- Albion Technology & General VCT PLC Voting Rights Update